UpcomingPDUFA target action date

Infigratinib (oral)

BridgeBio Pharma (BBIO)

Marketer take

An oral option in achondroplasia, where Voxzogo and Yuviwel are already approved, so expect route-of-administration messaging.

Sponsor company
BridgeBio Pharma (BBIO)
Indication
Achondroplasia
Therapeutic area
Endocrinology, Rare disease
Event
PDUFA target action date
Date
Feb 4, 2027
Status
Upcoming
Source
company press release
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move